IRIS
SCARTOZZI, MARIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.940
EU - Europa 983
AS - Asia 471
SA - Sud America 138
AF - Africa 58
Continente sconosciuto - Info sul continente non disponibili 4
Totale 3.594
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.934
UA - Ucraina 186
IT - Italia 155
SG - Singapore 138
SE - Svezia 135
BR - Brasile 122
IE - Irlanda 121
RU - Federazione Russa 115
TR - Turchia 102
CN - Cina 101
DE - Germania 85
DK - Danimarca 68
HK - Hong Kong 65
FI - Finlandia 60
KR - Corea 36
CI - Costa d'Avorio 35
GB - Regno Unito 30
FR - Francia 20
MA - Marocco 18
IN - India 9
JP - Giappone 7
BE - Belgio 5
CO - Colombia 5
CA - Canada 4
EU - Europa 4
VE - Venezuela 4
BD - Bangladesh 3
AR - Argentina 2
DZ - Algeria 2
IQ - Iraq 2
ZA - Sudafrica 2
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
CL - Cile 1
CZ - Repubblica Ceca 1
EC - Ecuador 1
EG - Egitto 1
IR - Iran 1
JM - Giamaica 1
KG - Kirghizistan 1
MM - Myanmar 1
MX - Messico 1
NL - Olanda 1
PE - Perù 1
PK - Pakistan 1
PL - Polonia 1
PY - Paraguay 1
UY - Uruguay 1
UZ - Uzbekistan 1
VN - Vietnam 1
Totale 3.594
Salva come PNG Salva come JPEG
Città #
Fairfield 210
Jacksonville 209
Chandler 199
Ashburn 157
Dublin 119
Wilmington 119
Des Moines 99
Boardman 96
Woodbridge 95
Seattle 76
New York 70
Houston 69
Hong Kong 65
Singapore 61
Cambridge 50
Centro 49
Lawrence 47
Princeton 47
San Mateo 43
Ann Arbor 42
Abidjan 34
The Dalles 29
Turin 28
Moscow 25
Helsinki 23
San Diego 22
Beijing 21
London 10
Washington 10
Pune 9
Curitiba 6
Kilburn 6
Los Angeles 6
Norwalk 6
Shanghai 6
São Paulo 6
Ancona 5
Belo Horizonte 5
Porto Alegre 5
Wuhan 5
Brussels 4
Chicago 4
Izmir 4
Munich 4
Rome 4
San Francisco 4
Bogotá 3
Jiaxing 3
Kagoya 3
New Bedfont 3
Redwood City 3
Toronto 3
Wuxi 3
Campinas 2
Clifton 2
Como 2
Cupra Marittima 2
Duque de Caxias 2
Fayetteville 2
Florence 2
Fortaleza 2
Foshan 2
Goiânia 2
Guangzhou 2
Guarulhos 2
Hounslow 2
Istanbul 2
Montesilvano 2
Rio Grande 2
Rio de Janeiro 2
San Jose 2
Sorocaba 2
Turku 2
Venice 2
Viamão 2
Zhengzhou 2
Acton 1
Alcobaça 1
Amsterdam 1
Andover 1
Anta Gorda 1
Aparecida 1
Aracaju 1
Arapongas 1
Arcoverde 1
Atlanta 1
Baku 1
Basra 1
Berlin 1
Betim 1
Bishkek 1
Bom Despacho 1
Brasília 1
Braço do Norte 1
Buffalo 1
Cachoeira 1
Cachoeira do Sul 1
Campina Grande 1
Caracas 1
Caraguatatuba 1
Totale 2.304
Salva come PNG Salva come JPEG
Nome #
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy 117
Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in clear cell renal cell carcinoma patients 107
Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: A multicentric retrospective analysis 105
Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab. 103
Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management 102
The role of micro-RNAs in hepatocellular carcinoma: from molecular biology to treatment 102
Clinical evidence for three distinct gastric cancer subtypes: time for a new approach. 97
Prognostic impact of mismatch repair genes germline defects in colorectal cancer patients: Are all mutations equal? 95
CANCER STEM CELL GENETIC PROFILE AS PREDICTOR OF RELAPSE IN RADICALLY RESECTED COLORECTAL CANCER 95
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study 95
VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib 92
BRAF-mutant colorectal cancer, a different breed evolving 91
Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation. 89
Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis 88
Role of β4 integrin in HER-3-negative, K-RAS wild-type metastatic colorectal tumors receiving cetuximab. 88
Translational challenges from the 2014 Gastrointestinal Cancers Symposium: Toward a true tailored therapy through effective research 88
Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients. 87
Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer 87
Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter 87
Beyond RAS: the role of epidermal growth factor receptor (EGFR) and its network in the prediction of clinical outcome during anti-EGFR treatment in colorectal cancer patients 85
The "angiogenetic ladder", step-wise angiogenesis inhibition in metastatic colorectal cancer 84
Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New 80
Prognostic Value for Incidental Antihypertensive Therapy With β-Blockers in Metastatic Colorectal Cancer 79
Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients 77
The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following? 76
Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma 76
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study 75
The challenge of targeted therapies for gastric cancer patients: The beginning of a long journey 74
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: Final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial 73
The distinctive molecular, pathological and clinical characteristics of BRAF-mutant colorectal tumors 72
Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients. 70
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy 70
Doses of capecitabine and oral vinorelbine are not relevant for efficacy in breast cancer patients: an analysis of dose intensity. 67
Tumor infiltrating lymphocytes in gastrointestinal tumors: Controversies and future clinical implications. 67
Systemic chemotherapy for advanced rare pancreatic histotype tumors: A retrospective multicenter analysis 67
Three drugs vs two drugs first-line chemotherapy regimen in advanced gastric cancer patients: a retrospective analysis 65
Selected gastrointestinal cancer presentations from the American Society of Clinical Oncology annual meeting 2013 in review: It is not about the destination, it is about the journey 64
Pharmacogenomics of cetuximab in metastatic colorectal carcinoma 63
Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world. 62
Tracking the 2015 gastrointestinal cancers symposium: Bridging cancer biology to clinical gastrointestinal oncology 62
Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded? 60
Selected news from the 2014 Genitourinary Cancers Symposium: Translating novel strategies into clinical practice 57
The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment 53
Cetuximab rechallenge in metastatic colorectal cancer patients: How to come away from acquired resistance? 52
Corrigendum: Cetuximab rechallenge in metastatic colorectal cancer patients: How to come away from acquired resistance? [Ann Oncol, 23, 9, (2012) (2313-2318)] doi: 10.1093/annonc/mdr623 51
Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: The TOREADOR Study 48
Thymidylate synthase, topoisomerase-1 and microsatellite instability: relationship with outcome in mucinous colorectal cancer treated with fluorouracil. Anticancer Res. 2013 Oct;33(10):4611-7 45
Totale 3.689
Salva come PNG Salva come JPEG
Categoria #
all - tutte 21.790
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.790
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202077 0 0 0 0 0 0 0 0 0 0 8 69
2020/2021735 48 85 78 7 140 40 46 65 50 78 52 46
2021/2022364 36 66 10 2 1 28 15 21 24 62 42 57
2022/2023745 52 93 51 42 37 165 0 38 177 5 75 10
2023/2024408 66 8 37 42 62 114 7 12 0 7 10 43
2024/2025724 122 67 15 13 39 41 104 34 162 66 61 0
Totale 3.689